Evidence map›Paper›PMID 32220278›Full record

ArticleLancet (London, England)2020

Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?

Andrew I Ritchie, Aran Singanayagam

Open access · bronzeAbstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Lancet (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 191 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
191citing papers in PubMed, 8 pooled it
6.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

191 citing papers in PubMed, 8 syntheses or guidelines pooled it, 294 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Article
  14. Article
  15. Article
  16. Article
  17. A20 as a Potential Therapeutic Target for COVID-19.Immunity, inflammation and disease · 2025
    Review
  18. Multidrug resistantCurrent research in microbial sciences · 2025
    Review
  19. Article
  20. Article

131 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Andrew I RitchieNational Heart and Lung Institute, Imperial College London, London SW7 2AZ, UK.
Aran SinganayagamNational Heart and Lung Institute, Imperial College London, London SW7 2AZ, UK; Royal Brompton and Harefield NHS Trust, London, UK. Electronic address: a.singanayagam@imperial.ac.uk.
Imperial College London · GBRoyal Brompton & Harefield NHS Foundation Trust · GB

Funding

Wellcome Trust
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CytokinesHeart Valve DiseasesImmunosuppression TherapyInflammationBetacoronavirusCoronavirus InfectionsCOVID-19HumansPandemicsPneumonia, ViralSARS-CoV-2Cytokines

Identifiers

PMID32220278
PMCPMC7138169
OpenAlexW3013376849

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.